Several polymorphisms and mutations of the TRAIL and TRAIL receptor genes have been suggested as risk or prognostic factors in lymphoid malignancies as well as breast, colon, liver, lung, and prostate cancer [31,32,33]. Here, TNFSF10 is linked to prostate cancer.